Status: Not yet recruiting
A Phase II Clinical Trial Evaluating the Efficacy and Safety of SYS6026 Injection in Participants With HPV16 or 18-related High-grade Cervical Squamous Intraepithelial Lesions
This trial is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study designed to evaluate the efficacy and safety of SYS6026 at different doses compared to placebo in treating patients with HPV16 or 18-related high-grade cervical squamous intraepithelial lesions (HSIL).
Participants needed: 175
Trial details
Phase: Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.Updated: Jul 14, 2026Locations: 1
Eligibility criteria
Age must be 18 years old or above; [+13]
Screening combined with other high-risk HPV subtypes (HPV 31, 33, 35, 39, 45, 51... [+19]